Scinai Immunotherapeutics (SCNI)

• Market cap: $1.54M
• 1 day: -3.75%
• 5 days: -3.75%
• 1 month: -25.24%
• 3 months: -46.71%
• 6 months: -53.89%
• Year to date: -55.23%
• 1 year: -63.07%
• 5 years: -99.96%
• 10 years: -99.55%
• Sector: Healthcare
• Industry: Biotechnology

About: Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

Employees: 31

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

89% more capital invested

Capital invested by funds: $45.2K [Q1] → $85.5K (+$40.3K) [Q2]

25% more funds holding

Funds holding: 4 [Q1] → 5 (+1) [Q2]

3.74% more ownership

Funds ownership: 0% [Q1] → 3.74% (+3.74%) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1